AbbVie (ABBV) to Release Quarterly Earnings on Friday

AbbVie (NYSE:ABBV - Get Free Report) is expected to be releasing its Q1 2025 earnings data before the market opens on Friday, April 25th. Analysts expect the company to announce earnings of $2.51 per share and revenue of $12.91 billion for the quarter. AbbVie has set its FY 2025 guidance at 12.120-12.320 EPS.

AbbVie (NYSE:ABBV - Get Free Report) last announced its earnings results on Friday, January 31st. The company reported $2.16 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.98 by ($0.82). AbbVie had a net margin of 7.59% and a return on equity of 296.28%. During the same period in the previous year, the firm posted $2.79 EPS. On average, analysts expect AbbVie to post $12 EPS for the current fiscal year and $14 EPS for the next fiscal year.

AbbVie Stock Down 1.7 %

NYSE ABBV traded down $2.98 on Monday, reaching $170.01. The company had a trading volume of 7,360,966 shares, compared to its average volume of 6,010,855. The company has a quick ratio of 0.55, a current ratio of 0.66 and a debt-to-equity ratio of 17.94. The stock has a market capitalization of $300.74 billion, a P/E ratio of 70.84, a P/E/G ratio of 1.62 and a beta of 0.55. The company's fifty day moving average is $198.01 and its 200 day moving average is $187.54. AbbVie has a 52-week low of $153.58 and a 52-week high of $218.66.

AbbVie Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, May 15th. Investors of record on Tuesday, April 15th will be given a dividend of $1.64 per share. This represents a $6.56 dividend on an annualized basis and a dividend yield of 3.86%. The ex-dividend date is Tuesday, April 15th. AbbVie's payout ratio is currently 273.33%.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. The Goldman Sachs Group reiterated a "neutral" rating and issued a $194.00 price objective on shares of AbbVie in a research note on Tuesday, April 8th. Citigroup upped their price objective on AbbVie from $205.00 to $215.00 and gave the company a "buy" rating in a research note on Monday, February 3rd. UBS Group lifted their target price on AbbVie from $181.00 to $190.00 and gave the stock a "neutral" rating in a research note on Monday, February 3rd. Guggenheim restated a "buy" rating and set a $214.00 price target on shares of AbbVie in a research report on Thursday. Finally, BMO Capital Markets raised their price objective on shares of AbbVie from $208.00 to $215.00 and gave the stock an "outperform" rating in a report on Monday, February 3rd. Seven analysts have rated the stock with a hold rating, seventeen have issued a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $210.71.

Insiders Place Their Bets

In other AbbVie news, EVP Perry C. Siatis sold 5,778 shares of AbbVie stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $197.90, for a total transaction of $1,143,466.20. Following the completion of the sale, the executive vice president now directly owns 22,381 shares in the company, valued at $4,429,199.90. The trade was a 20.52 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Jeffrey Ryan Stewart sold 58,832 shares of the stock in a transaction on Monday, March 31st. The stock was sold at an average price of $210.08, for a total transaction of $12,359,426.56. Following the completion of the transaction, the executive vice president now directly owns 53,234 shares in the company, valued at $11,183,398.72. The trade was a 52.50 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 113,471 shares of company stock worth $23,426,451 in the last three months. 0.25% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in AbbVie stock. Brighton Jones LLC lifted its position in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 17.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 22,912 shares of the company's stock after buying an additional 3,401 shares during the period. Brighton Jones LLC's holdings in AbbVie were worth $4,072,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 70.23% of the company's stock.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.